Yes, this is dyslipidemia—proceed with cardiovascular risk assessment and initiate statin therapy based on risk stratification.
Elevated LDL-C, total cholesterol, and non-HDL-C definitively meet criteria for dyslipidemia and require systematic cardiovascular risk evaluation followed by treatment.
Understanding the Diagnosis
Your patient has dyslipidemia characterized by elevations in multiple atherogenic lipid parameters. Non-HDL-C (calculated as total cholesterol minus HDL-C) captures all atherogenic lipoproteins including LDL, VLDL, IDL, and lipoprotein(a), making it a superior marker of cardiovascular risk compared to LDL-C alone, particularly when triglycerides are elevated 1, 2, 3.
Next Steps: Risk Stratification Algorithm
1. Determine Cardiovascular Risk Category
Classify the patient into one of these risk groups 1, 4, 5:
Very High Risk: Documented ASCVD (prior MI, ACS, stroke, PAD, coronary revascularization), type 2 diabetes with target organ damage, severe CKD (GFR <60), or 10-year ASCVD risk ≥10%
High Risk: Markedly elevated single risk factors (familial dyslipidemia, severe hypertension), diabetes without complications, moderate CKD, or 10-year ASCVD risk 5-10%
Moderate Risk: 10-year ASCVD risk 1-5%, typically middle-aged patients with multiple risk factors
Low Risk: 10-year ASCVD risk <1%
2. Calculate 10-Year ASCVD Risk (if no established disease)
Use validated risk calculators incorporating age, sex, smoking status, blood pressure, diabetes status, and lipid values 4, 5. This determines treatment intensity.
3. Set Treatment Targets Based on Risk
For Very High Risk patients 1:
- LDL-C goal: <70 mg/dL (1.8 mmol/L)
- Non-HDL-C goal: <100 mg/dL (2.6 mmol/L)
- Or achieve ≥50% reduction from baseline if starting between 70-135 mg/dL
For High Risk patients 1:
- LDL-C goal: <100 mg/dL (2.6 mmol/L)
- Non-HDL-C goal: <130 mg/dL (3.4 mmol/L)
- Or achieve ≥50% reduction from baseline if starting between 100-200 mg/dL
For Moderate Risk patients 4:
- LDL-C goal: <130 mg/dL
- Non-HDL-C goal: <160 mg/dL
Treatment Algorithm
Immediate Actions:
Initiate therapeutic lifestyle changes for ALL patients 4, 5:
- Reduce saturated fat to <7% of total calories
- Limit dietary cholesterol to <200 mg/day
- Increase soluble fiber intake (10-25 g/day)
- Achieve/maintain BMI 18.5-24.9 kg/m²
- Engage in ≥30 minutes moderate-intensity physical activity most days
Screen for secondary causes 6, 7:
- Check TSH (hypothyroidism)
- Liver function tests
- Renal function tests and urinalysis
- Fasting glucose/HbA1c (diabetes)
- Consider familial hypercholesterolemia if LDL-C >190 mg/dL in adults
Pharmacotherapy Decision:
Start statin therapy immediately (without waiting for lifestyle trial) if 1, 4, 5:
- Very high risk AND LDL-C ≥70 mg/dL
- High risk AND LDL-C ≥100 mg/dL
- Moderate risk with 10-year risk 10-20% AND LDL-C ≥130 mg/dL
- LDL-C ≥190 mg/dL (regardless of risk—suggests familial hypercholesterolemia)
Statin intensity selection 5:
- High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg): Very high risk patients
- Moderate-intensity statin (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg): High to moderate risk patients
If Goals Not Achieved on Maximally Tolerated Statin:
Add sequential therapy 1, 5, 8:
- Ezetimibe (reduces LDL-C by additional 15-20%)
- PCSK9 inhibitor (evolocumab, alirocumab) if very high risk and LDL-C remains ≥70 mg/dL
- Bempedoic acid as alternative if statin-intolerant
Critical Considerations for Non-HDL-C
Non-HDL-C becomes particularly important when 7, 2, 9:
- Triglycerides are 150-500 mg/dL (captures remnant lipoproteins)
- Patient has metabolic syndrome, diabetes, or obesity
- LDL-C is at goal but residual risk remains
The non-HDL-C target is always 30 mg/dL higher than the corresponding LDL-C target 7. This accounts for normal VLDL-C contribution and provides a more comprehensive assessment of atherogenic burden.
Common Pitfalls to Avoid
- Don't delay statin therapy in high/very high-risk patients waiting for lifestyle changes alone—start both simultaneously 1, 5
- Don't ignore non-HDL-C when triglycerides are elevated; it better predicts cardiovascular events than LDL-C in this scenario 2, 9, 3
- Don't undertreate young patients with markedly elevated lipids (LDL-C >190 mg/dL)—this suggests genetic dyslipidemia requiring aggressive therapy 1
- Don't stop at LDL-C goal if non-HDL-C remains elevated with high triglycerides—consider intensifying therapy 7, 10
Follow-Up Monitoring
- Recheck lipid panel 4-12 weeks after initiating or adjusting therapy 4
- Once at goal, monitor every 3-6 months initially, then annually if stable
- Assess adherence, adverse effects (myalgias, liver enzymes), and reinforce lifestyle modifications at each visit
The evidence strongly supports that earlier and more intensive lipid lowering translates to greater cardiovascular risk reduction—"the lower, the longer, the better" principle applies 11, 5.